Sino Biopharmaceutical CEO Eric Tse discusses the "survival" necessity of China's rapid clinical trial growth and his open-ended approach to deals in 2026. He speaks to Bloomberg TV's Haslinda Amin on ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback